Stan Berenshteyn, an analyst from Wells Fargo, reiterated the Buy rating on GoodRx Holdings. The associated price target remains the same with $7.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Stan Berenshteyn’s rating is based on several key factors that indicate potential growth for GoodRx Holdings. Despite facing challenges in prescription transactions due to external pressures like Rite-Aid store closures, these headwinds are expected to moderate. The company is poised to benefit from positive developments such as new ISP deals for employer coalitions, which could provide a boost in 2026.
Additionally, the subscription segment has stabilized and is anticipated to resume growth as GoodRx focuses more on consumer-directed products. The Manufacturing Solutions segment is highlighted as a significant growth driver, with an estimated 29% year-over-year increase in 2026. Even if revenue stalls, a 17% growth is projected, showcasing the segment’s resilience. These factors collectively contribute to the Buy rating, reflecting confidence in the company’s strategic initiatives and growth prospects.
In another report released on October 21, Citi also maintained a Buy rating on the stock with a $5.75 price target.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GDRX in relation to earlier this year.